Due to the COVID-19 pandemic, the ACP office is closed to the public as our staff work remotely. Click here to see how this impacts our programs and operations.

NAPRA drug schedule update

August 5, 2020

Extension: Ephedrine and Pseudoephedrine from the National Drug Schedules will remain Schedule III.

The National Association of Pharmacy Regulatory Authorities (NAPRA) recently updated its policy on Natural Health Products (NHPs) appearing in NAPRA’s National Drug Schedules (NDS). According to the new policy, all NHPs that were listed within the Unscheduled category and within Schedule III were removed from the NDS as of January 2, 2020.

At Health Canada’s request, ephedrine and pseudoephedrine will remain subject to the conditions of sales as outlined in NDS Schedule III until January 2, 2022. We previously communicated this extension would be in place until January 2, 2021; however, due to Health Canada’s focus on the COVID-19 pandemic throughout 2020, the extension will continue to January 2, 2022. This information is reflected on the NAPRA website.

Should you have any questions, please contact NAPRA at info@napra.ca.


← Previous ArticleNext Article →